Navigation Links
Endo Pharmaceuticals Solutions (Formerly Indevus Pharmaceuticals, Inc.) Announces Commencement of Offer to Purchase Its 6.25% Convertible Senior Notes Due 2009
Date:3/25/2009

LEXINGTON, Mass., March 25 /PRNewswire/ -- Endo Pharmaceuticals Solutions Inc. (formerly known as Indevus Pharmaceuticals, Inc.) today commenced an offer to purchase any or all of its outstanding 6.25% Convertible Senior Notes due 2009 in accordance with the indenture governing the Notes, as a result of the acquisition of Indevus by Endo Pharmaceuticals Holdings. The offer to purchase the Notes is scheduled to expire at 5:00 p.m., Eastern time, on April 22, 2009.

In the Notice of Change of Control and Offer to Purchase issued today, Endo Pharmaceuticals Solutions notified the holders of the Notes that the acquisition of approximately 77.972% of Indevus Common Stock by Endo Pharmaceuticals Holdings upon the closing of the initial offering period of the related tender offer on February 23, 2009, the election of a majority of new directors to the Indevus board of directors and the merger whereby Indevus, under its new name, Endo Pharmaceuticals Solutions, became a wholly-owned subsidiary of Endo Pharmaceuticals Holdings each resulted in a "change of control" (as defined in the indenture) and that each holder has the right to require Endo Pharmaceuticals Solutions to purchase its Notes. Pursuant to the Offer to Purchase, a holder who validly delivers all or a portion of Notes in acceptance of the offer prior to 5:00 p.m., Eastern time, on April 22, 2009 and does not withdraw the Notes prior to 5:00 p.m., Eastern time, on April 23, 2009 will be entitled to receive cash equal to 100% of the principal amount of such Notes, plus any accrued and unpaid interest to, but excluding, the change of control purchase date.

The Notes currently are convertible. Holders may convert any outstanding Notes into the right to receive (x) $676.0817 in cash for each $1,000 principal amount of Notes based on the conversion price of $6.656 and conversion rate of 150.2404 that was in effect at the effective time of the merger and the $4.50 initial cash
'/>"/>

SOURCE Endo Pharmaceuticals Solutions Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... With the swift industrial development of ... as smart phones, tablets and PDAs, a complete change ... devices are viewed these days. From only being used ... a mode for creating and delivering content while on ... , The complete makeover of this (mobile) ...
(Date:9/18/2014)... County, NY (PRWEB) September 18, 2014 ... Westchester residents, community advocates, and volunteers supported United ... annual “Best Chefs and Fine Wines” event Monday, Sept. ... United Way’s health initiatives in Westchester and Putnam, such ... obesity, and steering teens away from risky behaviors like ...
(Date:9/18/2014)... common Asian spice and cancer-hampering molecules show promise ... of the lung,s lining often linked to asbestos. ... Georg-Speyer-Haus in Frankfurt, Germany, demonstrate that application of ... cancer-inhibiting peptides increase levels of a protein inhibitor ... Their findings appeared in the Aug. 14 online ...
(Date:9/18/2014)... NC (PRWEB) September 18, 2014 October ... also Domestic Violence Awareness Month. And the Centers for ... tells a scary story. , According to the CDC ... fourth of men in the U.S. experience some form ... intimate relationship. The same survey shows that about half ...
(Date:9/18/2014)... 2014 With the arrival of subsequent-entry biologics ... Society released new resources to educate stakeholders on their potential ... guide SEB use, and patients must be well informed when ... Click here for an infographic and an expert video ... here for The Arthritis Society’s position paper on SEBs. ...
Breaking Medicine News(10 mins):Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 2Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 3Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 3Health News:What you should know about domestic violence 2Health News:What you should know about domestic violence 3Health News:What you should know about domestic violence 4Health News:What you should know about domestic violence 5Health News:Subsequent-entry biologics set to alter the arthritis treatment landscape 2
... Volumizing ... ... of the eyes change in generally predictable ways: the skin thins and becomes less elastic, ... eyes appear more prominent. While surgery has long been the accepted standard and offers ...
... , COLD SPRING HARBOR, N.Y., Aug. 17 ... Doctors Laboratory (TDL), the largest independent provider of clinical laboratory ... the world,s first hand-held, non-contact vein illumination device, to the ... locate veins for blood draw (venipuncture) by projecting a pattern ...
... , ALBANY, N.Y., Aug. 17 The ... August 17, 2009, is an Air Quality Action Day, a ... such as children, seniors and people with asthma and other ... pollution. The alert is issued for the New York downstate ...
... , , MCLEAN, Va., Aug. 17 ... His Cookie Helped 500,000 People Lose Weight Fast (2009, Hyde ... at CookieDiet.com, Amazon.com, Borders.com, and BN.com; at Barnes & Noble stores ... Biggest Bookstore, and Coles. , , "Dr. Siegal,s ...
... Finding will help predict patient response to therapy, researchers say ... that predicts a patient,s response to hepatitis C treatments has ... a single letter change -- a C instead of a ... gene, according to the Duke University Medical Center team. They ...
... , PRINCETON, N.J., Aug. 17 Derma ... a provider of advanced wound care products, reports results today for the second quarter ... for second quarter and six months ended June 30, 2009: , , ... to $664,766 in second quarter 2009, versus $295,315 in 2008. For the six months ...
Cached Medicine News:Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 3Health News:AccuVein Sells Multiple AV300s to First European Customer 2Health News:Air Quality Action Day Declared for Monday, August 17, 2009 2Health News:Dr. Siegal's Cookie Diet Book Available at Amazon, Barnes & Noble, and Indigo Books 2Health News:Dr. Siegal's Cookie Diet Book Available at Amazon, Barnes & Noble, and Indigo Books 3Health News:Dr. Siegal's Cookie Diet Book Available at Amazon, Barnes & Noble, and Indigo Books 4Health News:Genetic Discovery May Improve Hepatitis C Treatment 2Health News:Derma Sciences Reports Second Quarter 2009 Results 2Health News:Derma Sciences Reports Second Quarter 2009 Results 3Health News:Derma Sciences Reports Second Quarter 2009 Results 4Health News:Derma Sciences Reports Second Quarter 2009 Results 5Health News:Derma Sciences Reports Second Quarter 2009 Results 6Health News:Derma Sciences Reports Second Quarter 2009 Results 7Health News:Derma Sciences Reports Second Quarter 2009 Results 8
(Date:9/18/2014)... and LONDON , ... era for biopharmaceutical companies. Competition for innovation, increasing ... to keep up with the fast-changing environment are ... influence clinical trials, and clinical trial costs continue ... patient recruitment. Studies conducted by industry ...
(Date:9/18/2014)... , Sept. 18, 2014  ADM Tronics ... DeNovi , Ph.D. to its corporate Advisory Board ... an instructor at the Harvard Medical School and ... Rome.  He received his Masters degree in Electronics ... Systems from the University of Bologna. After spending a ...
(Date:9/18/2014)... , Sept. 18, 2014 MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today that it has entered into a ... MiMedx will provide its dehydrated human amnion/chorion membrane ... non- exclusively on a private label basis. ...
Breaking Medicine Technology:Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3
... and secondary endpoints of,study; no negative drug-drug ... CAMBRIDGE, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- ... phase II study,designed to evaluate triple combination ... candidate for the,treatment of hepatitis C, pegylated ...
... II Study Demonstrates Significant,Additional Improvement for Patients ... /PRNewswire-FirstCall/ --,Indevus Pharmaceuticals, Inc. today announced that ... for pagoclone in persistent,developmental stuttering will be ... the New Clinical Drug Evaluation Unit (NCDEU), ...
Cached Medicine Technology:Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 2Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 3Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 4Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 5Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 7Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 8Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 9
Resorbable fixation system 1.5/2.0....
... Sonomed-315 is intended for visualization of the ... midline shifts in the brain, evaluation of ... to use, the Sonomed-315 offers quick and ... allows to identify the anatomic structures of ...
... cost, low volume alternative. Whole blood is drawn ... from whole blood by centrifugation in a standard ... Cebus single use cartridge. The cartridge is then ... the concentrating process. Finally, the cartridge is spun ...
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: